Skip to main content

Table 1 Comparison of clinical and molecular characteristics with miR-425 expression in AML patients

From: MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy

Characteristic

Chemotherapy group

Allo-HSCT group

High miR-425 (n = 45)

Low miR-425 (n = 45)

P

High miR-425 (n = 36)

Low miR-425 (n = 36)

P

Age/years, median (range)

63 (22–88)

68 (33–83)

0.138

52 (25–72)

50 (18–69)

0.450

Age group/no. (%), years

  

0.652

  

0.793

 < 60

16 (35.6)

13 (28.9)

 

27 (75.0)

25 (69.4)

 

 ≥ 60

29 (64.4)

32 (71.1)

 

9 (25.0)

11 (30.6)

 

Gender/no. (%)

  

0.289

  

1.000

 Male

28 (62.2)

22 (48.9)

 

21 (58.3)

20 (55.6)

 

 Female

17 (37.8)

23 (51.1)

 

15 (41.7)

16 (44.4)

 

WBC/× 109/L, median (range)

15.2 (0.7–298.4)

16.9 (1.0–297.4)

0.589

30.3 (1.5–98.8)

28.3 (0.6–223.8)

0.978

BM blast/ %, median (range)

67 (30–98)

75 (37–99)

0.050

68 (30–97)

76 (35–100)

0.131

PB blast/%, median (range)

18 (0–71)

53 (0–98)

0.002

41 (0–85)

53 (0–96)

0.116

FAB subtypes/no. (%)

 M0

0 (0.0)

8 (17.8)

0.006

3 (8.3)

6 (16.7)

0.478

 M1

7 (15.6)

13 (28.9)

0.201

8 (22.2)

15 (41.7)

0.129

 M2

13 (28.9)

8 (17.8)

0.231

13 (36.1)

6 (16.7)

0.107

 M4

14 (31.1)

10 (22.2)

0.340

8 (22.2)

6 (16.7)

0.767

 M5

9 (20)

4 (8.9)

0.230

3 (8.3)

1 (2.8)

0.614

 M6

0 (0.0)

1 (2.2)

1.000

1 (2.8)

0 (0.0)

1.000

 M7

1 (2.2)

1 (2.2)

1.000

0 (0.0)

1 (2.8)

1.000

 Others

1 (2.2)

0 (0.0)

1.000

0 (0.0)

1 (2.8)

1.000

Karyotype/no. (%)

 Normal

21 (46.7)

23 (51.1)

0.833

17 (47.2)

17 (47.2)

1.000

 Complex

5 (11.1)

7 (15.6)

0.758

5 (13.9)

7 (19.4)

0.753

 MLL rearranged

2 (4.4)

1 (2.2)

1.000

2 (5.6)

1 (2.8)

1.000

 CBFβ-MYH11

7 (15.6)

0 (0.0)

0.012

5 (13.9)

0 (0.0)

0.054

 BCR-ABL1

1 (2.2)

0 (0.0)

1.000

1 (2.8)

1 (2.8)

1.000

 RUNX1-RUNX1T

5 (11.1)

1 (2.2)

0.203

0 (0.0)

1 (2.8)

1.000

 Others

4 (8.9)

13 (28.9)

0.029

6 (16.7)

9 (25)

0.563

Risk (cyto)/no. (%)

 Good

12 (26.7)

1 (2.2)

0.002

5 (13.9)

1 (2.8)

0.199

 Intermediate

20 (44.4)

30 (66.7)

0.056

17 (47.2)

24 (66.7)

0.153

 Poor

13 (28.9)

12 (26.7)

1.000

13 (36.1)

11 (30.6)

0.803

 Others

0 (0.0)

2 (4.4)

0.494

1 (2.8)

0 (0.0)

1.000

FLT3-ITD/no. (%)

  

1.000

  

0.396

 Presence

8 (17.8)

8 (17.8)

 

6 (16.7)

10 (27.8)

 

 Absence

37 (82.2)

37 (82.2)

 

30 (83.3)

26 (72.2)

 

NPM1/no. (%)

  

0.367

  

0.430

 Presence

12 (26.7)

17 (37.8)

 

8 (22.2)

12 (33.3)

 

 Absence

33 (73.3)

28 (62.2)

 

28 (77.8)

24 (66.7)

 

DNMT3A/no. (%)

  

0.059

  

0.415

 Presence

8 (17.8)

17 (37.8)

 

7 (19.4)

11 (30.6)

 

 Absence

37 (82.2)

28 (62.2)

 

29 (80.6)

25 (69.4)

 

RUNX1/no. (%)

  

0.058

  

1.000

 Presence

1 (2.2)

7 (15.6)

 

4 (11.1)

4 (11.1)

 

 Absence

44 (97.8)

38 (84.4)

 

32 (88.9)

32 (88.9)

 

MLL-PTD/no. (%)

  

1.000

  

0.115

 Presence

2 (4.4)

3 (6.7)

 

4 (11.1)

0 (0.0)

 

 Absence

43 (95.6)

42 (93.3)

 

32 (88.9)

36 (100.0)

 

TP53/no. (%)

  

1.000

  

1.000

 Mutation

5 (11.1)

5 (11.1)

 

2 (5.6)

2 (5.6)

 

 Wild type

40 (88.9)

40 (88.9)

 

34 (94.4)

34 (94.4)

 

CEBPA/no. (%)

  

1.000

  

1.000

 Mutation

2 (4.4)

1 (2.2)

 

4 (11.1)

4 (11.1)

 

 Wild type

43 (95.6)

44 (97.8)

 

32 (89.9)

32 (88.9)

 

IDH1/no. (%)

  

0.012012

  

0.514

 Mutation

0 (0.0)

7 (15.6)

 

4 (11.1)

7 (19.4)

 

 Wild type

45 (100.0)

38 (84.4)

 

32 (88.9)

29 (80.6)

 

IDH2/no. (%)

  

1.000

  

0.710

 Mutation

4 (8.9)

5 (11.1)

 

3 (8.3)

5 (13.9)

 

 Wild type

41 (91.1)

40 (88.9)

 

33 (91.7)

31 (86.1)

 
  1. WBC white blood cell, BM bone marrow, PB peripheral blood, FAB French–American–British classification, MLL mixed-lineage leukemia, FLT3-ITD internal tandem duplication of the FLT3 gene, NPM1 nucleophosmin, DNMT3A DNA methyltransferase 3A, RUNX1 runt related transcription factor 1, MLL-PTD partial tandem duplication of the MLL gene, CEBPA CCAAT/enhancerbinding protein α, IDH isocitrate dehydrogenase
  2. The median expression level of miR-425 was used to define high- and low-miR-425-expression groups. P values for continuous variables are from Mann–Whitney test; P values for categorical variables are from Chi square tests. The values represent frequencies (%). Complex karyotype is defined as more than or equal to 3 chromosomal abnormalities. The patients were divided into three risk groups (good, intermediate and poor) according to the cytogenetic risk classification
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us